Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 10:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Hypertension, Prehypertension, Aging
Interventions: Inspiratory muscle strength training, Sham training; Other
Lead sponsor: Douglas Seals; Other
Eligibility: 50 Years to 64 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Hypertension (HTN), Obesity & Overweight
Interventions: Mind Your Heart, DASH Diet Education; Behavioral
Lead sponsor: University of Georgia; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Athens, Georgia

Conditions: Hypertension
Interventions: Patient education; Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: CTEPH
Interventions: Macitentan Tablets, Riociguat, balloon pulmonary angioplasty; Drug · Device
Lead sponsor: Dr Sudarshan Rajagopal; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hypertension
Interventions: Patient Activation Measure Intervention Package; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 21 Years and older
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Primary Open Angle Glaucoma
Interventions: iStent, Cataract surgery; Device · Procedure
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 22 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 14
States / cities: Irvine, California • Montebello, California • Aurora, Colorado + 11 more

Conditions: Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion, Glaucoma
Interventions: Apraclonidine 1.0% ophthalmic solution; Drug
Lead sponsor: Retina Consultants of Delmarva; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Easton, Maryland

Conditions: Hypertension
Interventions: Blood pressure education; Behavioral
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 75 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Glaucoma, Open Angle or Ocular Hypertension
Interventions: brinzolamide 1% ophthalmic suspension, Azopt 1%; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Glaucoma
Interventions: Micropulse Transscleral Cyclophotocoagulation; Procedure
Lead sponsor: Wills Eye; Other
Eligibility: 20 Years to 85 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Normal Blood Pressure, Controlled Hypertension, Uncontrolled Hypertension
Interventions: ABPMPro, Spacelabs Ambulatory Blood Pressure Monitoring, Aktiia Blood Pressure, LiveMetric, Bpro; Device
Lead sponsor: Stephen Juraschek; Other
Eligibility: 18 Years to 100 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pre-eclampsia
Interventions: Anti-digoxin antibody (FAB fragment), sodium chloride; Drug · Other
Lead sponsor: BTG International Inc.; Other
Eligibility: Female only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 8
States / cities: Mobile, Alabama • Phoenix, Arizona • Orlando, Florida + 5 more

Conditions: Preeclampsia
Interventions: Salsalate Oral Tablet, Placebo Oral Tablet; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Iowa City, Iowa • University Park, Pennsylvania

Conditions: Hypertensive Disorder of Pregnancy
Interventions: Postpartum Remote Physical Activity Intervention; Behavioral
Lead sponsor: Jackie Dziewior; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Hypertension, Elevated Cholesterol, Overweight and Obesity
Interventions: Dietary Intervention; Other
Lead sponsor: Texas Woman's University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hypertension
Interventions: LCI699, Eplerenone, LCI699-matching Placebo, Eplerenone-matching Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 37
States / cities: Mobile, Alabama • Sierra Vista, Arizona • Buena Park, California + 34 more

Conditions: Glaucoma
Interventions: Water Drinking Test; Procedure
Lead sponsor: Wills Eye; Other
Eligibility: 21 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hypertension
Interventions: Relaxation response; Behavioral
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 55 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metabolic Syndrome X, Overweight, Hypertension, Dyslipidemias, Prediabetic State
Interventions: Placebo Comparator: First Intervention (3 weeks), Active Comparator: Second Intervention (3 weeks), Active Comparator: Third Intervention (3 weeks), Active Comparator: Fourth Intervention (3 weeks); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 60 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: T2DM (Type 2 Diabetes Mellitus), Hypertension, Heart Disease Chronic, Stroke, Hyperlipidemias, Peripheral Vascular Diseases, Obesity
Interventions: Virtual Group Visit; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Chicago, Illinois • Orland Park, Illinois

Conditions: Elevated Intraocular Pressure
Interventions: Latanoprost ophthalmic solution, 0.005%, TC-002 latanoprost ophthalmic solution, 0.005%; Drug
Lead sponsor: TearClear Corp; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 20
States / cities: Garden Grove, California • Glendale, California • Mission Hills, California + 16 more

Conditions: Hyperlipidemia, Hypertension, Diabetes, Medication Nonadherence
Interventions: Adherence Intervention; Other
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 5,421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Bloomington, Minnesota

Conditions: Pulmonary Hypertension, Sickle Cell Anemia, Sickle Cell Disease
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older
Enrollment: 986 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Pulmonary Arterial Hypertension PAH
Interventions: Exercise, Standard of Care; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Rochester, New York

Search by objective public record fields.

Inspiratory Muscle Strength Training to Improve Blood Pressure and Physiological Function

University of Georgia Mind Your Heart Pilot Study

Achieving Blood Pressure Control Through Enhanced Discharge

Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPH

The Effect of the Patient Activation Measure on Chronic Care

Multicenter Post-Approval Study Of The Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery

Iopidine to Decrease Intraocular Pressure Rise After Injections

Evaluating the Effect of an Evidence-Based One Page With Supplemental Visual Aids on the Knowledge and Perceptions of Blood Pressure Management Among Adults With Hypertension

Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt

How Safe and Effective is Micropulse Transscleral Cyclophotocoagulation in Patients With Uncontrolled Glaucoma?

Wearable Evaluation of Ambulatory Readings for Blood Pressure

Efficacy Study of Digibind for Treatment of Severe Preeclampsia

Angiotensin II and Chronic Inflammation in Persistent Microvascular Dysfunction Following Preeclampsia

Remote Postpartum Intervention Targeting Movement Behaviors After Hypertensive Disorders of Pregnancy

Effects of a 4-week Raw, Plant-based Diet on Anthropometric and Cardiovascular Risk Factors

A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension

Comparing the Effect of the Water Drinking Test on Intraocular Pressure

Mechanisms and Therapeutic Effects of the Relaxation Response in Elderly Hypertensive Patients

Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)

Virtual Diabetes Group Visits Across Health Systems

Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure

Medication Adherence Clinical Decision Support

Secondary Pulmonary Hypertension in Adults With Sickle Cell Anemia

Home Rehabilitation Improves Cardiac Effort in Pulmonary Arterial Hypertension